VIVORYON THERAPEUTICS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4735 EUR | -1.35% |
|
-5.68% | -94.18% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Calendar
2024-06-11
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.48
EUR
Average target price
41.57
EUR
Spread / Average Target
+8,559.72%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -94.18% | 13.3M | |
| +48.77% | 42.16B | |
| -0.97% | 42.07B | |
| +4.36% | 39.77B | |
| -11.36% | 26.68B | |
| +3.87% | 24.68B | |
| -23.35% | 18.68B | |
| -1.72% | 12.11B | |
| +25.62% | 11.99B | |
| +5.32% | 11.06B |
- Stock Market
- Equities
- VVY Stock
- News Vivoryon Therapeutics N.V.
- Vivoryon Therapeutics N : Licenses Alzheimer's Disease Drugs to China's Simcere Pharmaceutical
